Asimov

Asimov is a Boston-based synthetic biology company founded in 2017 that combines AI/machine learning with genetic engineering to create a comprehensive design platform for advanced therapies. The company's core offering is an end-to-end platform featuring engineered GMP host cells, a vast library of validated genetic parts, and cloud-based design software, which it provides to partners either as transferable tools or as a full-service cell line development offering. Asimov's technology demonstrates impressive performance benchmarks, such as achieving biologics titers of 8-12 g/L with its CHO Edge platform, positioning it as a key enabler for the next generation of biologic and cell and gene therapy manufacturing.

An integrated platform combining engineered mammalian host cell lines (CHO, LV, AAV), a library of validated genetic parts, and cloud-based AI/ML design software (Kernel) for the end-to-end design and optimization of genetic systems for therapeutic production.

Asimov competes in the computational synthetic biology space against other startups like Ginkgo Bioworks (though more focused on non-mammalian systems) and Arpeggio Biosciences, as well as divisions of large life science tools companies (e.g., Thermo Fisher, Sartorius) that are adding software and services to their portfolios. Its deep focus on mammalian systems and therapeutic production is a key differentiator.